Myovant Sciences and Pfizer Announce Collaboration

The FINANCIAL -- Myovant Sciences and Pfizer Inc. today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s health in the U.S. and Canada. Pfizer will also receive an exclusive…

4 mins read